

REMARKS

The specification has been amended to correct minor informalities. The amendments are supported in the specification and do not raise new matter issues

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attachment is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

In the event any additional fees are required, please charge our Deposit Account No. 111833.

Respectfully submitted,

KUBOVCIK & KUBOVCIK



Keiko Tanaka Kubovcik
Reg. No. 40,428

Atty. Case No. NPR-082
The Farragut Building
Suite 710
900 17th Street, N.W.
Washington, D.C. 20006
Tel: (202) 887-9023
Fax: (202) 887-9093
KTK/cfm

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The paragraph beginning at page 18, line 11 has been amended as follows:

--As apparent from Table 5, while the amino acid solution had no significant effect of decreasing the coma period compared with the control group, the ammonia concentration in the blood was reduced significantly. On the other hand, the HSA alone showed no effect on the coma period or the ammonia concentration in the blood. However, the albumin preparation in which more than 0.01 w/v % of [~~HAS~~] HSA was added to the amino acid solution in the present invention showed a significant effect on decreasing of the coma period and reducing the ammonia concentration in the blood.--

The table at page 19, Table 6, has been amended as follows:

Table 6

composition	number of animals	[ema] <u>coma</u> period (min)	concentration of ammonia in the blood ($\mu\text{mol/dL}$)
Physiological saline	8	30 \pm 3	123 \pm 7
1.0 % BSA	6	23 \pm 3	119 \pm 10
[amine] <u>Amino</u> acid solution	6	17 \pm 2**	94 \pm 9*
[amine] <u>Amino</u> acid solution + 0.1 % BSA	6	7 \pm 3***	100 \pm 4*
[amine] <u>Amino</u> acid solution + 1.0 % BSA	6	5 \pm 3***	69 \pm 13**

Numbers show mean value \pm standard error.